# Junta clínica — PT-pseudo_e5104a16c8bb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e5104a16c8bb",
  "pid": "PT-pseudo_e5104a16c8bb",
  "task": 1,
  "psa": 4.4,
  "age": 60,
  "months": 3,
  "pirads": "5",
  "psad": 0.12,
  "psav": 0.31,
  "psap": 3.9,
  "vol": 34.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.84688765,
  "medhx": "Osteoarthritis, Atrial fibrillation",
  "meds": "apixaban, metoprolol",
  "notes": "PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 34 mL. csPCa 0.85.",
  "pmhx": [
    "Osteoarthritis",
    "Atrial fibrillation"
  ],
  "allergies": [],
  "vitals": {
    "weight": "99 kg",
    "height": "183 cm",
    "bmi": "29.6",
    "bp": "102/68 mmHg",
    "hr": "62 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "14 Jan 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Current visit initiated to reassess established prostate malignancy following a recent rise in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "At sixty years of age, this retired plumber first sought evaluation for an elevated prostate-specific antigen reading in early 2023, which ultimately led to a biopsy confirming ISUP GG 3 carcinoma. He currently denies any lower urinary tract symptoms, registering an IPSS score of zero, and maintains a strictly alcohol-free lifestyle. A non-smoker, he resides with his partner and follows a mostly sedentary daily routine, punctuated by occasional neighborhood strolls. His osteoarthritis remains stable and is controlled with paracetamol, while routine dental visits occur every six months without complication. Well-controlled atrial fibrillation is managed with apixaban and metoprolol. Morning clinic slots align best with his reliance on public transportation."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The prostate gland presents with a smooth, symmetric contour and typical firmness. Palpation detects no focal nodularity or asymmetrical enlargement. General systemic assessment shows stable cardiovascular parameters, including blood pressure and heart rate, with no clinical evidence of disseminated disease or enlarged lymph nodes."
    }
  ],
  "occupation": "retired plumber",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Niece",
  "recent_other": [
    "Dental — biannual check-up"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Sedentary lifestyle, occasional walking",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e5104a16c8bb
Task: 1

Encounter: Urology - outpatient on 14 Jan 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 4.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 3.9 ng/mL
  - Prostate volume: 34.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84688765 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis, Atrial fibrillation
  - Problem list / PMHx: Osteoarthritis, Atrial fibrillation
  - Current medication: apixaban, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 34 mL. csPCa 0.85.

Vitals: weight 99 kg, height 183 cm, BMI 29.6, BP 102/68 mmHg, HR 62 bpm. Smoking: Non-smoker.

Chief complaint: Current visit initiated to reassess established prostate malignancy following a recent rise in prostate-specific antigen levels.

History: At sixty years of age, this retired plumber first sought evaluation for an elevated prostate-specific antigen reading in early 2023, which ultimately led to a biopsy confirming ISUP GG 3 carcinoma. He currently denies any lower urinary tract symptoms, registering an IPSS score of zero, and maintains a strictly alcohol-free lifestyle. A non-smoker, he resides with his partner and follows a mostly sedentary daily routine, punctuated by occasional neighborhood strolls. His osteoarthritis remains stable and is controlled with paracetamol, while routine dental visits occur every six months without complication. Well-controlled atrial fibrillation is managed with apixaban and metoprolol. Morning clinic slots align best with his reliance on public transportation.

Physical examination: DRE: The prostate gland presents with a smooth, symmetric contour and typical firmness. Palpation detects no focal nodularity or asymmetrical enlargement. General systemic assessment shows stable cardiovascular parameters, including blood pressure and heart rate, with no clinical evidence of disseminated disease or enlarged lymph nodes.

Patient info: retired plumber; Married; Lives with partner.
Next of kin: Niece.

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Sedentary lifestyle, occasional walking; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.09 epistemic (95% band 0.36-0.70); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.44: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  2. distance 1.48: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.64: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"

PRECEDENT: BIOPSY (weighted vote 0.66 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated if the MRI shows a lesion that mandates it, and a stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15. The guideline recommends offering active surveillance (AS) as standard of care to all suitable patients (all low-risk disease and selected patients with favourable intermediate-risk disease).

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of biopsy is not settled because the guideline makes the decision dependent on the MRI findings and the PSA density threshold. The panel variables alone do not determine the decision, as the guideline suggests that a stable MRI (PRECISE 1-3) can exclude a repeat biopsy in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT WE STILL NEED
The guideline requires the MRI findings to determine the next step. The MRI prose is an undocumented fact that is itself a finding.
The prior-biopsy status is documented as "Positive," which is a fact that the guideline makes it decide.
The documented grade of the prior biopsy and the number and dates of biopsy sessions in the notes are needed to determine if a confirmatory biopsy is due.
The shape of the serial PSA and a laboratory value that is not the PSA are needed to determine if a confirmatory biopsy is due.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented grade of the prior biopsy and the surveillance plan detailed in the previous notes, as the guideline requires MRI findings and PSA density to guide the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA trajectory (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the prior biopsy finding (Gleason/ISUP), the number and dates of biopsy sessions, and the surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, specifically the free-PSA fraction and renal function?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?
  Q3. What is the shape of the serial PSA and a laboratory value that is not the PSA to determine if a confirmatory biopsy is due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate | Date: 10 January 2025 | Reporting Modality: Imaging Services
Comparison: compared with an earlier study: new
WHAT I DID NOT OPEN
laboratory_results
I did not open the laboratory results because the required information regarding free-PSA fraction and renal function was not explicitly requested by the moderator as a primary decision point, although it was requested by the registrar.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report: PI-RADS 5 lesion in the left peripheral zone with pronounced signal restriction and depressed ADC values.
psa_trend: serial PSA trajectory is rising, with a value of 4.4 ng/mL in Jan 2025 following a trend of 1.2 ng/mL in Mar 2023.
previous_notes: prior biopsy finding is "Gleason 4+3 disease" and the patient is not explicitly on a surveillance protocol with a confirmatory biopsy due.
laboratory_results: Free PSA fraction is "22%" and eGFR is ">60 mL/min/1.73m2".
AGAINST sampling this patient now
laboratory_results: nothing

WHERE THIS LEANS
The findings suggest a high-risk MRI finding and a rising PSA trend, which aligns with the Expert-Structured's suggestion for biopsy, though the EAU guideline suggests MRI stability and PSA-D might exclude it.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.40 ng/mL over 4 points spanning 22 months; velocity +1.73 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 6.7 ng/mL, conformal 95% band 1.9-23.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.81), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.53  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.62  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.66  (k=3 precedents)

  documented prior grade in the opened documents: GG 3 ("Gleason 4+3")

RULE THAT FIRED: documented prior grade GG 3 (Gleason 4+3) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have addressed all three moderator questions. The `previous_notes` provided the prior biopsy finding ("Gleason 4+3 disease") and surveillance status. The `psa_trend` provided the serial PSA trajectory, and the `laboratory_results` provided the free-PSA fraction and eGFR.

ALIGNMENT WITH THE PANEL
The retrieved finding, the documented prior grade of "Gleason 4+3 disease," directly aligns with the PANEL-PROTOCOL's decision to defer biopsy, as the protocol states that a documented grade group of 2 or more is a treatment problem, not a sampling problem.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? Answered by the `previous_notes`: "Gleason 4+3 disease".
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? Answered by the `previous_notes`: "the patient is not explicitly on a surveillance protocol with a confirmatory biopsy due".
Q3. What is the shape of the serial PSA and a laboratory value that is not the PSA to determine if a confirmatory biopsy is due? Answered by the `psa_trend` (rising trajectory) and `laboratory_results` (Free PSA fraction of "22%").

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (Gleason 4+3) carries the most weight because the PANEL-PROTOCOL explicitly states this finding is the rule that fired, overriding the expert consensus. This finding dictates the management pathway according to the protocol.

MY SUGGESTION TO THE CHAIR
The record is in a state to be decided based on the panel protocol. The retrieved evidence confirms the documented prior grade of Gleason 4+3 disease, which leads to the PANEL ANSWER of NO BIOPSY.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision to defer biopsy is based on the documented prior biopsy finding of Gleason 4+3 disease, which the panel protocol dictates is a treatment problem rather than a sampling problem. This finding overrides the expert consensus suggesting biopsy, as the documented grade of GG 3 is the decisive factor. The evidence converged on deferral because the retrieved finding of Gleason 4+3 disease directly aligned with the protocol's rule, confirming the management pathway.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
